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Abstract
A better understanding of the molecular mechanisms that participate in the development and clinical manifestations
of schizophrenia can lead to improve our ability to diagnose and treat this disease. Previous data strongly associated
the levels of deregulated ADAMTS2 expression in peripheral blood mononuclear cells (PBMCs) from patients at first
episode of psychosis (up) as well as in clinical responders to treatment with antipsychotic drugs (down). In this current
work, we performed an independent validation of such data and studied the mechanisms implicated in the control of
ADAMTS2 gene expression. Using a new cohort of drug-naïve schizophrenia patients with clinical follow-up, we
confirmed that the expression of ADAMTS2 was highly upregulated in PBMCs at the onset (drug-naïve patients) and
downregulated, in clinical responders, after treatment with antipsychotics. Mechanistically, ADAMTS2 expression was
activated by dopaminergic signalling (D1-class receptors) and downstream by cAMP/CREB and mitogen-activated
protein kinase (MAPK)/ERK signalling. Incubation with antipsychotic drugs and selective PKA and MEK inhibitors
abrogated D1-mediated activation of ADAMTS2 in neuronal-like cells. Thus, D1 receptors signalling towards CREB
activation might participate in the onset and clinical responses to therapy in schizophrenia patients, by controlling
ADAMTS2 expression and activity. The unbiased investigation of molecular mechanisms triggered by antipsychotic
drugs may provide a new landscape of novel targets potentially associated with clinical efficacy.
Introduction
Antipsychotic drugs (APDs) remain the standard
pharmacological treatment for schizophrenia (SCZ) and
psychotic disorders, mainly by targeting dopamine neu-
rotransmission (primarily D2 receptors)
1–3. APDs can be
classified into typical (i.e., haloperidol) and atypical (i.e.,
aripiprazole, risperidone or clozapine), the latter pre-
scribed as first-line drugs and/or in refractory patients4.
Despite the effectiveness of APDs in the clinical realm,
there is a marked disparity among patients with respect to
symptoms, responses and side effects5,6. Whereas 50–60%
of patients achieve an optimal degree of clinical
improvement of positive symptoms, little to no
improvement of negative symptoms or cognitive deficits is
common5. Overall, estimates suggest that one-fifth to
one-half of patients have treatment-resistant SCZ and
about 30–60% of these respond to clozapine6–8. These
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evidences suggest that although D2 receptors is a direct
target for all drugs used to treating SCZ, its blockade may
not tackle the primary biological anomaly in a significant
percentage of patients9. In this respect, the combined D1
and D2 receptors antagonism has been proposed to have
synergic effects, which could account for the atypical
clinical effectiveness of clozapine10. From a molecular
perspective, the effects of APDs may also include the
modulation of D2 receptor-independent mechanisms
through indirect effects, such as, e.g., those related to
other metabotropic receptors implicated in the control
cAMP-dependent signalling11 and/or those related with
receptor-biased agonism4,12. Downstream of cAMP, the
activation of protein kinase A (PKA) promotes phos-
phorylation of DARPP-32 (a cytosolic protein), which has
been associated with the pathophysiology of SCZ13,14. In
addition, the glutamate hypothesis of SCZ led to explore
its potential clinical application as targets for therapy15.
The investigation of the mechanisms downstream of the
receptors targeted by APDs will certainly guide to finding
out new explanations for pathophysiological mechanisms
and novel approaches for therapy4.
A new paradigm has emerged based on the investigation
of transcriptional patterns associated with clinical
responses in SCZ, raising the likelihood of revealing
unknown molecular mechanisms associated with anti-
psychotic action that may be crucial in accomplishing
optimal clinical responses16,17. Using an unbiased tran-
scriptome approach, we have previously described a set of
genes that are differentially expressed at the onset of
SCZ16. In addition to this, we also showed significant
differential gene expression elicited after a 3-month APD
treatment in responder patients17. Among the above-
mentioned results, ADAMTS2 was the highest upregu-
lated gene in SCZ patients at the onset of the disease and
also was the most significant downregulated gene, back to
‘healthy levels’, in responder patients to treatment with
APDs. The observation that the expression of ADAMTS2
can be modulated by APDs and its association with
clinical response, makes it an appealing candidate to
investigate its interface with illness pathology and clinical
efficacy17.
In the present work we initially performed an inde-
pendent validation using a new cohort of drug-naïve non-
affective psychosis patients. We confirmed that
ADAMTS2 expression was significatively overexpressed at
diagnosis, and that treatment with APDs reduced their
expression levels back to ‘healthy’ values, which, in turn,
was associated with clinical responses (positive symp-
toms). However, the molecular or cellular mechanisms
exerted by APDs to regulate ADAMTS2 expression are
unknown. Following a bottom-up strategy starting from
the transcriptional data obtained in SCZ cases and taking
advantage of neuronal-like cells towards the identification
of membrane receptors and the intracellular mechanism
controlled by them, we herein provide new evidence that
ADAMTS2 expression is regulated by dopaminergic sig-
nalling cascade (D1-class receptors) through ERK and
cAMP/cAMP response element-binding protein (CREB)
activities.
Materials and methods
Human samples and study setting
Human samples for this study were obtained from an
ongoing epidemiological and 3-year longitudinal inter-
vention programme of first-episode psychosis (PAFIP)
conducted at the University Hospital Marques de Valde-
cilla (Cantabria, Spain) and biological samples were pro-
vided by the IDIVAL biobank. The study was approved by
the Cantabria Ethics Institutional Review Board, con-
forming to international standards for research ethics.
Patients meeting inclusion criteria and their families
provided written informed consent to be included in
the PAFIP.
A new independent set of 30 APD-naïve, first-episode
non-affective individuals and 10 healthy individuals
(without a history of neuropsychiatric disorders) were
used to validate gene expression profiles related to clinical
response (Table 1).
Briefly, all patients underwent a head-to-head risper-
idone and aripiprazole randomized (simple randomization
procedure), flexible-dose, open-label study (EudraCT
number 2013-005399-16). More detailed information
about PAFIP and treatment protocol has been published
elsewhere17,18 and also is briefly available in Supplemen-
tary Information.
RNA extraction
Peripheral blood from patients and controls was
extracted using the TempusTM Blood RNA Tube
(Applied Biosystems, UK). Peripheral blood mononuclear
cell (PBMC) isolation was performed using a Ficoll-Paque
Premium reagent (Sigma) and total mRNA isolation using
a TempusTM Spin RNA Isolation Kit (Invitrogen, CA,
USA), following the manufacturer’s instructions. RNA
Integrity Number (RIN) was characterized with a Bioa-
nalyzer (Agilent Technologies) and samples with a RIN >
8 were selected. Total mRNA from culture cells was
extracted using Trizol reagent (Invitrogen) and its con-
centration was determined using a Nanodrop 2000 spec-
trophotometer (Thermo Scientific, IL, USA).
RT-PCR and quantitative PCR
cDNA synthesis was performed using the SuperScript
IV Reverse Transcriptase (Invitrogen). cDNA was ampli-
fied using the Power SYBR™ Green PCR Master Mix
(Applied Biosystems) in a 7300 Fast Real-Time PCR
System (Applied Biosystems). Specific oligos for human
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ADAMTS2, CREB1, and C-FOS were designed using
Primer-Blast (NCBI; see sequences in Supplementary
Table S1). ACTB expression was used to normalize values.
Gene expression changes were determined using 2(–ΔΔCt)
formula. A melting curve was generated for every run to
confirm assay specificity.
Cell culture and treatments
Human neuroblastoma (SK-N-SH, ATCC HTB-11) and
293T (ATCC CRL-3216) cells were obtained from the
American Type Cell Collection (Rockville, MD). Cells
were cultured in modified Eagle’s medium and Dulbecco’s
Modified Eagle’s Medium, respectively (Corning, VA,
USA). Culture medium was supplemented with 10% dia-
lysed fetal bovine serum (dFBS; HyClone, UT, USA),
glucose, L-glutamine, streptomycin sulphate and potas-
sium penicillin (10,000 U/L) (Lonza, Belgium).
Drugs and pharmacological agents
Aripiprazole, clozapine, haloperidol hydrochloride, H89
dihydrochloride, L 741,626, MDL 100907, paliperidone,
risperidone, SKF 83822, SCH 39166, TCB-2, WAY
Table 1 Psychopathological characteristics at baseline, at 3 months and clinical changes during the follow-up period.
Comparison between aripiprazole and risperidone.





Mean SD Mean SD Mean SD
CGI
Baseline 6.5 0.6 6.56 0.51 6.43 0.65 t= 0.63c 0.532
3 Months 1.8 1.2 1.63 1.20 2.00 1.24
3-Month change from baseline −4.7 1.2 z= 4.83a 0.000 −4.90 0.30 −4.47 0.33 F= 0.96d 0.336
YMRS
Baseline 13.8 6.2 14.25 7.24 13.29 5.01 t= 0.42c 0.679
3 Months 1.2 2.3 1.56 2.63 0.79 1.93
3-Month change from baseline −12.6 6.5 z= 4.78a 0.000 −12.25 0.59 −13.00 0.63 F= 0.75d 0.394
CDSS
Baseline 1.5 3.0 2.06 3.82 0.86 1.75 t= 1.08c 0.288
3 Months 1.2 2.3 1.19 2.34 1.14 2.25
3-Month change from baseline −0.3 3.7 z= 0.35a 0.724 −0.34 0.59 −0.32 0.63 F= 0.00d 0.985
BPRS
Baseline 70.3 15.0 69.06 16.08 71.85 13.95 t=− 0.49c 0.627
3 Months 29.9 7.1 29.06 7.07 30.92 7.48
3-Month change from baseline −40.4 15.2 t= 14.32b 0.000 −41.13 1.81 −39.53 2.01 F= 0.35d 0.561
SAPS
Baseline 15.9 4.2 15.63 3.50 16.07 4.94 t=− 0.29c 0.775
3 Months 0.6 1.7 0.69 1.89 0.71 1.49
3-Month change from baseline −15.4 4.3 t= 19.28b 0.000 −15.14 0.44 −15.12 0.47 F= 0.00d 0.975
SANS
Baseline 4.8 6.9 3.47 6.56 5.93 7.43 t=− 0.95c 0.352
3 Months 3.9 6.6 4.00 6.47 4.93 7.04
3-Month change from baseline −0.9 5.6 z= 1.14a 0.255 −0.07 1.54 −0.36 1.59 F= 0.02d 0.899
BPRS Brief Psychiatric Rating Scale, CDSS Calgary Depression Rating Scale for Schizophrenia, CGI Clinical Global Impression, SANS Scale for the Assessment of Negative
Symptoms, SAPS Scale for the Assessment of Positive Symptoms, YMRS Young Mania Rating Scale
aWilcoxon matched-pairs signed-rank test
bPaired Student’s t-test
cComparison between aripiprazole and risperidone at baseline; unpaired Student’s t-test
dComparison between aripiprazole and risperidone following the antipsychotic treatment, using the total score of the clinical scales at baseline as covariate; analysis
of covariance (ANCOVA)
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100635, 7-OH-DPAT and 8-OH-DPAT were purchased
from Tocris Bioscience (Spain). Forskolin and selumetinib
(AZD6244) were purchased from Selleckchem (Spain).
Cholera toxin (CTX), pertussis toxin (PTX) and 12-O-
tetradecanoylphorbol-13-acetate (TPA) were purchased
from Sigma-Aldrich (MO, USA). YM-254890 was pur-
chased from Adipogen Life Sciences (CA, USA). All were
dissolved in dimethyl sulfoxide, except CTX and WAY
100635 that were dissolved in water.
Luciferase report assays
Luciferase report assays were performed by transfection
with 0.5 µg DNA of the following plasmids mix (ratio 3:1):
pGL4.29[luc2P/CRE/Hygro] containing firefly luciferase
reporter, alongside pRL-Null containing Renilla luciferase
used as control (Promega, WI, USA). Cells were trans-
fected with Lipofectamine LTX with PLUS reagents
(Invitrogen) in transient conditions. Firefly and Renilla
levels were detected using Dual-Luciferase Reporter Assay
System kit and quantified using a GloMax-Multi appara-
tus (Promega).
Western blotting
Cells were starved overnight before treatment. Whole
cell lysates were obtained using RIPA buffer (Sigma)
supplemented with phosphatase and protease inhibitors
(Roche, Germany). Protein expression was analysed by
western blotting as described previously19. Briefly, anti-
bodies used were as follows: phospho-CREB, CREB,
phospho-ERK1/2, ERK1/2, phospho-p38, p38, and
phospho-PKA substrates (Cell Signaling, MA, USA), and
β-Tubulin (Santa Cruz Biotechnology). Fluorophore
conjugate antibodies were obtained from Invitrogen.
Signals were visualized and recorded with an Odyssey
Infrared Imaging scanner (LI-COR Biosciences, NE,
USA). Immunoblot densitometry analysis on every band
was calculated using Image Studio Software (LI-COR
Biosciences). Phosphorylation and total protein densito-
metry values were normalized to β-Tubulin signal.
CREB knocked down reagents and procedures
ShCREB1-inducible SK-N-SH cells were generated by
lentiviral infection of SK-N-SH cells with SMARTvector
carrying tGFP and human inducible CREB1 short hairpin
RNA (shRNA) mCMV constructs or non-target control
shRNA (Dharmacon, CO, USA). Lentiviral particles were
produced by co-transfection of 293T cells using Trans-
Lentiviral shRNA Packaging System (Dharmacon),
according to the manufacturer’s protocol. Cells were
incubated with doxycycline (1 μg/ml) (Sigma) for 72 h to
induce green fluorescent protein and shRNA expression.
SK-N-SH cells expressing stable shCREB1 constructs
were generated by direct transfection by Lipofectamine
LTX with PLUS reagent (Invitrogen) using pGFP-V-RS-
CREB1 shRNA expression vectors or scrambled control
(Origene, MD, USA). Transfected cells were selected with
puromycin (1 μg/mL) at least 7 days.
Statistical analyses
Kolmogorov–Smirnov test and Levene test were used to
test normality and equality of variances, respectively.
For patients’ studies, to ensure group comparability
between healthy volunteers and patients, socio-
demographic and clinical characteristics at baseline were
tested by unpaired Student’s t-test or one-way analysis of
variance (ANOVA) for continuous variables as necessary,
and by Fisher’s exact test for qualitative variables (Table 1
and Supplementary Table S2).
Wilcoxon’s signed-rank test for independent data was
used to compare the ADAMTS2 mRNA expression level
among healthy volunteers and drug-naïve patients at
baseline. Wilcoxon’s matched-pairs signed-rank test for
paired data was performed to compare the change in the
mRNA expression level from baseline to 3 months fol-
lowing the antipsychotic treatment (α= 0.05). STATA
15.1 was used for statistical analysis.
For in vitro studies, unless otherwise specified, all
experiments were independent and numerical data were
summarized as the mean ± SEM using GraphPad
Prism6 software. Each global mean was compared using
unpaired Student’s t-test (two tailed; α= 0.05) or one-way
ANOVA followed by post-hoc test where appropriated, as
described in each figure legend.
Results
ADAMTS2 expression is controlled by APD treatment in
SCZ patients
To better evaluate the mechanistic effects of atypical
APDs in SCZ patients, we prepared and studied a new
cohort of 30 drug-naïve SCZ patients with baseline
quantitative data (sociodemographic and clinical char-
acteristics) and clinical follow-up data, after 3 months of
treatment with APDs (Table 1). We found significant
within-subject changes between baseline data and after
3 months of treatment in both risperidone and aripipra-
zole groups. These changes were observed in CGI (Clin-
ical Global Impression, p < 0.000), YMRS (Young Mania
Rating Scale, p < 0.000), BPRS (Brief Psychiatric Rating
Scale, p < 0.000) and SAPS (Scale for the Assessment of
Positive Symptoms, p < 0.000) total scores. However, as it
is shown in Table 1, no differences were found in total
scores of the clinical scales when the two APD groups
were compared at baseline and after 3 months of
treatment.
To analyse transcriptomic changes, we obtained PBMCs
isolated from blood samples from SCZ patients, which
were obtained at the first episode of psychosis (onset) and
after a 3-month period of treatment with APDs. In this
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context, using quantitative reverse transcriptase PCR (RT-
qPCR), we performed an independent validation of tran-
scriptional changes by focusing on ADAMTS2. Thus, we
confirmed ADAMTS2 as a significant gene that was highly
overexpressed at the onset, with respect to healthy con-
trols, and downregulated by APDs after 3 months of
treatment (Fig. 1).
Dynamic control of ADAMTS2 transcription by APDs in
neuronal-like cells
To gain mechanistic insight into the transcriptional
control of ADAMTS2, we analysed the effects of APDs in
SK-N-SH cells using dFBS. No significant differences in
ADAMTS2 expression were observed when dFBS was not
present in the culture medium (data not shown). These
cells express cell surface receptors that are targets of
APDs (i.e., D1, D2, 5-HT1A and 5-HT2A receptors) as well
as detectable basal expression of ADAMTS2 mRNA. Our
data showed that incubation with APDs in these cells
induced dynamic changes in ADAMTS2 mRNA expres-
sion along time. Incubation with atypical APDs such as
paliperidone, aripiprazole (Fig. 2) and risperidone (Sup-
plementary Fig. S1), provoked a dynamic inhibition of
ADAMTS2 basal mRNA expression in these cells with fast
(<1 h) but transitory responses. Interestingly, clozapine
(atypical APD) and haloperidol (typical APD) induced a
fast and sustained (up to 24 h) inhibition of ADAMTS2
expression (Fig. 2).
Neurotransmitter receptors and associated signalling
pathways involved in the control of ADAMTS2 gene
expression
Using selective agonists for D1, D2, 5-HT1A and 5-HT2A
receptors in SK-N-SH cells, we observed that SKF 83822
(a D1-class receptor agonist) significantly triggered
ADAMTS2 mRNA expression compared with the lack of
effect of 7-OH-DPAT, 8-OH-DPAT and TCB-2 (agonists
of D2, 5-HT1A and 5-HT2A receptors, respectively)
(Fig. 3a). In addition, using selective antagonists for these
receptors, we observed that only SCH 39166 (a D1-class
receptor antagonist) significantly downregulated
ADAMTS2 mRNA expression, whereas L 741,626, WAY
100635 and MDL 100907 (antagonists of D2, 5-HT1A and
5-HT2A receptors, respectively) were devoid of this effect
(Fig. 3a). Furthermore, we analysed ADAMTS2 mRNA
and protein expression profiles in the brain of developing
and early postnatal mice (see Supplementary Methods).
Interestingly and in support of our previous results in
Fig. 1 Transcriptional control of ADAMTS2 in SCZ patients at
onset and after 3-month antipsychotic treatment. Relative mRNA
expression level of ADAMTS2 gene in PBMCs from peripheral blood
samples of an independent cohort of SCZ patients: healthy controls
(basal; grey bar), untreated FEP patients (basal drug-naïve; black bar)
and 3-month treated patients (striped bar). FEP: first episode of
psychosis. All patients were treated with risperidone or aripiprazole
drugs and showed clinical response to treatment (Cohort: patients N
= 30 and controls N= 10). Data are mean ± SEM; unpaired Wilcoxon’s
signed-rank test: ***p < 0.001 compares patients at baseline vs. healthy
controls; paired Wilcoxon’s signed-rank test: ###p < 0.001 compares
patients at baseline vs. those after 3-month AP treatment. Fig. 2 Transcriptional control of ADAMTS2 using antipsychotic
drugs. Relative ADAMTS2 mRNA expression level in SK-N-SH cells
incubated with clozapine (1 µM) (N= 4), haloperidol (1 µM) (N= 5),
paliperidone (1 µM) (N= 3) and aripiprazole (1 µM) (N= 5) for the
indicated times. Data are mean ± SEM; one-way ANOVA for multiple
comparations: *p < 0.05, **p < 0.01, ***p < 0.001 shows significance
with respect to control (C; vehicle, grey bars).
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Fig. 3 (See legend on next page.)
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cells, ADAMTS2 was specifically localized in brain
regions that are part of the mesolimbic and mesocortical
dopamine systems (Supplementary Fig. S2).
Next, we studied whether treatment with APDs could
modulate ADAMTS2 gene expression activated down-
stream of the D1 receptor. Our results show that haloper-
idol and clozapine could significantly block SKF 83822-
mediated transcriptional activation of ADAMTS2. As
expected, SCH 39166, a selective D1 receptor antagonist,
also prevented D1 receptor-mediated activation of
ADAMTS2 (Fig. 3b). In addition, the reduction in
ADAMTS2 expression induced by clozapine was prevented
by L 741,626 and MDL 100907 (a D2 and 5-HT2A receptor
antagonists, respectively) (Supplementary Fig. S3).
As D1 receptors are known to signal through Gαs, we
sought to confirm its role at controlling ADAMTS2
expression in our system, alongside Gαi and Gαq. For this
purpose, we incubated SK-N-SH cells with CTX (Gαs
activator), PTX (Gαi inhibitor) and YM-254890 (a specific
Gαq inhibitor)
20, before activating D1 receptors with SKF
83822. The activation of Gαs (Supplementary Fig. S4A)
and the inhibition of Gαi (Supplementary Fig. S4B) per se
significantly upregulated ADAMTS2 expression. More-
over, the inhibition of Gαi potentiated ADAMTS2
expression after D1 receptor activation (Supplementary
Fig. S4B). Finally, the inhibition of Gαq did not modify the
basal and the SKF 83822-mediated increase of ADAMTS2
expression (Supplementary Fig. S4C).
Incubation of neuronal-like cells with the selective D1
receptor agonist (SKF 83822) provoked rapid phosphor-
ylation of CREB and ERK1/2 (15 min), and no changes in
p38 (Supplementary Fig. S4D-F). In addition, rapid
phosphorylation of PKA substrates was detected in
response to SKF 83822 (Supplementary Fig. S4G). To
evaluate CREB-dependent transcriptional activity in
neuronal-like cells, we took advantage of a CRE-luciferase
reporter. We analysed if APDs could counteract the
intracellular signalling activation mediated by selective
SKF 83822 D1-class receptor agonist. Our results (Fig. 3c)
demonstrate that preincubation with clozapine, but not
haloperidol, paliperidone, or aripiprazole, prevented SKF
83822-induced CREB activation using a specific
reporter assay.
To evaluate the potential contribution of PKA and ERK
to the activation of ADAMTS2 expression, we incubated
SK-N-SH cells with SKF 83822 D1 receptor agonist in
combination with selective MAPK/ERK (selumetinib-
AZD6244) and cAMP/PKA (H89 dihydrochloride) inhi-
bitors. Both inhibitors prevented D1 receptor induced
expression of ADAMTS2 (Fig. 3d), although only a cAMP/
PKA inhibitor abrogated CREB-dependent transcription
and phosphorylation (Fig. 3e, f).
Transcriptional mechanisms controlling ADAMTS2 gene
expression downstream of dopamine D1 receptors
Our previous data suggest that there is a rapid activa-
tion of the signalling mechanisms controlling CREB
activation after D1 receptor activation that can be
modulated pharmacologically. We decided to challenge
the contribution of cAMP/CREB signalling to the tran-
scriptional activation of ADAMTS2 (Fig. 4a). We initially
evaluated the activation of ADAMTS2 gene expression
together with that of C-FOS, an ‘early response gene’
known to be a direct transcriptional target of CREB that
was used as control. Our data showed that SKF 83822
activated mRNA expression of both ADAMTS2 and C-
FOS. Interestingly, incubation with forskolin alone (a
selective adenyl cyclase activator) was sufficient to trigger
the transcription of both genes, whereas TPA (a PKC/
MAPK activator) uniquely activated C-FOS transcription.
To explore the implication of CREB in D1 receptor-
mediated ADAMTS2 expression, we generated stable SK-
N-SH cells with inducible expression of control or CREB1
shRNAs upon addition of doxycycline to the culture
media. Using this approach, we reduced CREB1 mRNA
and protein expression, as shown in Fig. 4b. Under these
settings, SKF 83822 and forskolin failed to induce the
expression of ADAMTS2 (Fig. 4c). Interestingly, SKF
(see figure on previous page)
Fig. 3 Neurotransmitter receptors and associated signalling pathways involved in the control of ADAMTS2 gene expression. a ADAMTS2
mRNA levels by RT-qPCR in SK-N-SH cells incubated 1 h with the indicated selective receptor agonist (red bars): SKF 83822 (D1-class receptors) (N= 5),
7-OH-DPAT (D2-class receptors) (N= 3), 8-OH-DPAT (5-HT1A receptor) (N= 3) and TCB-2 (5-HT2A/2C receptors) (N= 5); and selective antagonist (blue
bars): SCH 39165 (D1-class receptors) (N= 3), L 741,626 (D2-class receptors) (N= 4), WAY 100635 (5-HT1A receptors) (N= 3) and MDL 100907 (5-HT2A
receptors) (N= 3) (Drug concentration 1 µM). b ADAMTS2 mRNA levels by RT-qPCR in cells incubated for 1 h with SKF 83822 (N= 4) and pre-
incubated also for 30 min with SCH 39166 (N= 4), clozapine (N= 3), haloperidol (N= 4), paliperidone (N= 4) or aripiprazole (N= 4) (Drug
concentration 1 µM). c CREB activity in cells transfected with CRE-Luc alongside pRL-Null: cells were pre-incubated for 1 h with the indicated APDs
and then, incubated for 24 h with SKF 82833 (10 µM) (N= 4). d ADAMTS2 mRNA levels by RT-qPCR: SK-N-SH cells were pre-incubated for 30 min with
MAPK/ERK and cAMP-PKA inhibitors (selumetinib 1 µM N= 6 and H89 10 µM N= 4, respectively) and then, incubated for 1 h with SKF 82833 (1 µM)
(N= 5). e CREB activity in cells transfected with CRE-Luc alongside pRL-Null (N= 4): SK-N-SH cells were pre-incubated for 1 h with the indicated
inhibitors and then incubated for 24 h with SKF 82833 (10 µM). fWestern blottings showing relative phosphorylation levels of CREB and ERK1/2: SK-N-
SH cells were pre-incubated for 1 h with the indicated inhibitors and then incubated for 15 min with SKF 82833 (1 µM) (N= 3). Blots are
representative images of each western-blot. Data are mean ± SEM; Student’s t-test: *p < 0.05 and ***p < 0.001 vs. control condition (vehicle), and #p <
0.05, ##p < 0.01, ###p < 0.001 vs. SKF 83822 condition.
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83822 did not significantly activate C-FOS expression in
CREB1 knocked down cells when compared with control
cells; in contrast, TPA did (Fig. 4d). A schematic repre-
sentation of the signalling pathways and the molecules
used in this work is illustrated in Fig. 5 for explanatory
purposes. The above-mentioned results were further
confirmed using SK-N-SH cells stably expressing control
or CREB1 shRNAs (Supplementary Fig. S5). Mechan-
istically, reduced CREB expression did not impair ERK
phosphorylation elicited downstream of D1 receptor
activation by SKF 83822 (Fig. 4e). In this context, we also
used forskolin and TPA as controls for selective activation
of CREB and ERK, respectively (Fig. 4e and Supplemen-
tary Fig. S6). Thus, activation of CREB seems to play a key
role in the control of ADAMTS2 gene expression down-
stream of D1 receptors.
Discussion
Our results revealed that treatment with APDs control
ADAMTS2 expression, which is directly associated with
dopaminergic signalling, primarily with the D1-class
receptors and downstream through cAMP/CREB and
MAPK signalling. Interestingly, ADAMTS2 mRNA and
protein were specifically found in mesolimbic and meso-
cortical dopaminergic regions in mice. Our data suggest
that D1 receptor signalling towards CREB activation and
its effects on ADAMTS2 expression may be linked to key
biological mechanisms in SCZ and the clinical response to
APDs21,22.
In the context of the local PAFIP programme, we
collected a new cohort of 30 drug-naïve SCZ patients
with associated clinical data and follow-up. Using these
cases alongside ‘healthy’ controls, we attempted an
independent validation of our previous results using a
different cohort of cases16,17. In this cohort, we con-
firmed ADAMTS2 as a significant gene that was highly
overexpressed at baseline in PBMCs from drug-naïve
SCZ individuals and which returned to ‘normal’ levels in
clinical responders treated with APDs (clinical rate
scales in Table 1). Although, there is not always a direct
correlation between the biomarkers obtained in per-
ipheral blood cells and the central nervous system
(CNS) samples, a previous study in a rodent model of
SCZ have shown a certain parallelism between the
expression in human PBMCs16,17 and mouse frontal
cortex samples23. Supporting the previously mentioned
data, ADAMTS2 mRNA expression was quickly down-
regulated by all APDs in neuronal-like cells. Moreover,
whereas the activities of paliperidone, risperidone, and
aripiprazole downregulating ADAMTS2 mRNA were
transitory in such cells, those of clozapine and halo-
peridol were sustained to up to 24 h. The molecular
effects exerted by clozapine and haloperidol as com-
pared with other APDs might deserve further
investigations. In this respect, clozapine has shown
superior efficacy for treatment-resistant and suicidality,
as well as its apparent ability to decrease substance use
in SCZ24. Thus, ADAMTS2 might play a key, and yet to
be defined, mechanistic role in both the illness onset and
clinical responses, regardless of the type of APD used.
There is scarce information regarding specific ADAMTS2
expression and activity in the CNS. Therefore, we analysed
the expression profiles of ADAMTS2 mRNA and protein in
mice. Interestingly, these were specifically localized in brain
regions that are part of the mesolimbic and mesocortical
dopamine systems (i.e., the dentate gyrus in the hippocampus
and the ventral tegmental area21,22,25. At a prenatal stage
(E18.5), ADAMTS2 protein was mapped in the neuropiles of
anterior brain structures, anterior cingulate cortex, superficial
striatum and lateral septum, where neuronal expression of
dopamine D1 and D2 receptors was detected by in situ
hybridization (http://developingmouse.brain-map.org/). The
hypothesis that dopamine and dopaminergic mechanisms are
essential to psychosis, and particularly to SCZ, has been one
of the most enduring ideas about this disorder26. Elevated
presynaptic striatal dopamine correlates most closely with
the symptom dimension of psychosis and blockade of this
heightened transmission leads to a resolution of symptoms
for most patients27. Nonetheless, the functional association
between ADAMTS2 and the dopaminergic system has not
been previously established, to our best knowledge.
ADAMTS2 is a member of the ADAM Metallopeptidase
with Thrombospondin family28,29, with a number of targets
such as the N-propeptides of procollagens I–III, fibronectin,
decorin and Dkk3 participating in extracellular matrix (ECM)
organization, as well as in transforming growth factor (TGF)-
β and WNT signalling30,31. Alterations in the ECM as well as
TGF-β and WNT signalling have been associated with
SCZ32–34. Moreover, deregulated mRNA expression of
MMPs (MMP-16, -24 and -25) and ADAMTS (ADAMTS-1,
-6 and -8) families of proteases have also been reported in
SCZ35,36. Thus, considering ADAMTS2 expression and its
associated activities in the CNS, as well as the data presented
in this work, it is conceivable to speculate that it could
participate in SCZ at different stages of the disease. In this
regard, a selective D1-class receptor agonist (SKF 83822)
significantly activated ADAMTS2 expression, and haloperidol
and clozapine blocked this activation in neuronal-derived
cells. It will be of interest, to address these appealing ques-
tions, within the next future, using SCZ and/or ADAMTS2
transgenic mice models.
D1 receptors are the most abundant dopaminergic
receptor in CNS and their functional crosstalk with D2
receptor is well documented11,37,38. D1 receptor activate
adenylyl cyclase (AC), which in turn regulate intracellular
cAMP levels leading to PKA activation and CREB phos-
phorylation39–41. Our data have shown that selective D1
receptor activation upregulated ADAMTS2 expression
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Fig. 4 Transcriptional mechanisms that control ADAMTS2 gene expression downstream of dopamine D1-class receptors. a RT-qPCR showing
ADAMTS2 and C-FOS mRNA expression level in SK-N-SH cells incubated for 1 h with SKF 83822 (1 µM; blue bars) (N= 6 and N= 4, respectively),
forskolin (10 µM; red bars) (N= 3 and N= 4, respectively) and TPA (10 ng/ml; green bars) (N= 3). b CREB1 knockdown SK-N-SH cells by lentiviral
inducible shRNA and GFP reporter construct (yellow bars), incubated with doxycycline (1 µg/ml) for 72 h, CREB1 mRNA level (up) and CREB protein
total expression (down) in non-targeted control (NTC) or shCREB1 cells (N= 3). Inducible CREB1 Knockdown SK-N-SH cells were incubated for 1 h
with SKF 83822 (1 µM, blue bars), forskolin (10 µM, red bars) and TPA (10 ng/ml, green bars): RT-qPCR showing ADAMTS2 (c) and C-FOS (d) mRNA
expression in inducible shCREB1 or non-targeted control (NTC) cells incubated with doxycycline (1 µg/ml) for 72 h (N= 3-4). e Shows western
blottings using anti-phospho-CREB and anti-phospho-ERK, as well as anti-CREB and anti-ERK antibodies: inducible shCREB1 or non-targeted control
(NTC) SK-N-SH cells incubated with doxycycline (1 µg/ml) for 72 h and then incubated for 15 min with SKF 83822 (1 µM), forskolin (10 µM) and TPA
(10 ng/ml) (N= 3). Inducible knockdown cells were selected with puromycin (1 µg/ml) at least 7 days. Blots images are representative of independent
experiments. Data are mean ± SEM; Student’s t-test: *p < 0.05, **p < 0.01, ***p < 0.001 vs. vehicle or doxycycline (−); and #p < 0.05, ###p < 0.001 vs.
each condition in NTC cells.
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alongside a rapid phosphorylation of CREB and ERK pro-
teins, which resulted in CREB-mediated transcriptional
activity as detected by using specific reporter assays (Fig. 3).
In support of this and in our system, ADAMTS2 tran-
scription was specifically triggered by activation of D1
receptors (by SKF 83822), Gαs (using CTX) and AC (for-
skolin). Thus, it is possible that, as part of the dopaminergic
activity, ADAMTS2 could act as a major cAMP/CREB
effector in SCZ. Interestingly, D1 receptor-mediated CREB
activation was abrogated by clozapine (Fig. 3c), providing
evidence that cAMP/CREB signalling, and therefore
ADAMTS2 expression, can be modulated by APDs. Our
findings reveal the contribution of D1 receptors over
ADAMTS2 transcription, and also indicate the participation
of D2 and 5-HT2A receptors in the effect of clozapine in the
control of ADAMTS2 expression. In this regard, it has been
reported that clozapine can act as a biased agonist on
5-HT2A receptors
42,43 and/or affect the hetero-dimer D2/
5-HT2A
44. Moreover, disrupting cAMP/CREB and ERK
signalling using selective PKA and MEK inhibitors also
impaired ADAMTS2 expression and CREB activity (in this
case, only when it was PKA dependent) in neuronal-like
cells. Supporting these observations, recent data pointed at
cAMP/CREB signalling as an important mechanism linking
dopaminergic signalling with the pathophysiology of SCZ45.
Moreover, incubating SK-N-SH cells with forskolin was
sufficient to trigger ADAMTS2 expression that occurred
alongside PKA and CREB activation. Forskolin directly
activates AC in mammals, thereby promoting a rapid
phosphorylation of CREB via PKA46,47. In addition, in
CREB-knockdown cells, D1 receptor activation failed to
increase ADAMTS2 gene expression, reinforcing the idea
that cAMP/CREB is an essential mechanism to control
ADAMTS2 transcriptional activation.
Finally, a number of potential limitations could be
considered when interpreting our data and the scope of
our findings: (1) sample size in this study is rather small
(N= 30). Noteworthy, we selected a group of patients
with a first episode of non-affective psychosis, who had
not previously taken APDs (not even a single dose) at the
time of baseline blood test to avoid any interference with
the mRNA levels. Only those individuals who gave written
consent and had mRNA samples at baseline and at
3 months were eligible for this study. Therefore, all these
stringent inclusion criteria limited the number of patients
in this cohort. Further investigations to replicate our
findings using larger and more heterogeneous groups are
warranted. (2) Transcriptomic data obtained from blood
samples might not resemble that of the brain. (3)
ADAMTS2 protein and mRNA expression show modest
but detectable levels in ‘healthy’ human and mouse brain
samples (https://www.proteinatlas.org). Thus, it is con-
ceivable to detect high fold increases when analysing
diseased specimens, like in this case ADAMTS2 in SCZ.
(4) Failure of some APDs to inhibit CREB activity and/or
ADAMTS2 mRNA expression in a D1 receptor-context.
Our data herein do not discard that APDs might regulate
ADAMTS2 by indirect mechanisms like for example those
involving β-arrestin, ERK or AKT signalling42,48.
In conclusion, we have confirmed the association
between ADAMTS2 expression and SCZ disease includ-
ing its potential role in the clinical efficacy of APDs.
Transcription of ADAMTS2 is primarily controlled by the
activity of D1-class receptors through cAMP/CREB and
MAPK signalling. The unbiased investigation of the
molecular mechanisms triggered by APDs, may provide a
landscape of novel targets potentially associated with
improved therapeutic responses.
Acknowledgements
We are highly indebted to the participants and their families for their
cooperation in this study. We also thank IDIVAL biobank (Inés Santiuste and
Jana Arozamena) for clinical samples and data as well as the PAFIP members
(Marga Corredera) for the data collection. This work was supported by:
SAF2016-76046-R and SAF2013-46292-R (MINECO and FEDER) to B.C.F., PI16/
00156 (isciii and FEDER) to J.P.V., LUCHAMOS POR LA VIDA project to F.R.J. and
J.P.V., SAF2017-83702-R (MINECO and FEDER), Red TERCEL RD12/0019/0024
(ISCIII) and GVA-PROMETEO 2018/041 (Generalitat Valenciana) to S.M. J.P.V. is
Fig. 5 Schematic representation of the mechanisms that control
ADAMTS2 gene expression. Selective stimulation of D1 receptors by
SKF 83822 (selective D1 receptor agonist) triggers the expression of
ADAMTS2. Two main pathways seem to be involved: (1) Gαs/AC/cAMP/
PKA signalling and (2) MEK/ERK1/2 signalling. Downstream of D1 both
PKA and ERK can phosphorylate CREB at Ser133 and activate
transcription of ADAMTS2. Specific activators of PKA (Forskolin) and
MEK (TPA) are highlighted in blue. Specific inhibitors of PKA (H89) and
MEK (selumetinib) are coloured in red. DA D1 (dopamine D1 receptor),
Gsα (G-protein α-subunit), Gβγ (G-protein βγ-subunits), AC (adenyl
cyclase), PKA (protein kinase A), CRE (cyclic AMP-responsive element)
site and PM (plasmatic membrane). Arrows: direct interaction, dashed
arrows: indirect interaction.
Ruso-Julve et al. Translational Psychiatry           (2019) 9:306 Page 10 of 12
supported by the RyC research programme (RYC-2013-14097) and F.R.J. by the
predoctoral research programme (BES-2014-070615), from MINECO and FEDER.
Author details
1Department of Psychiatry, University Hospital Marqués de Valdecilla-IDIVAL,
Santander 39011 Cantabria, Spain. 2Department of Molecular Biology, School
of Medicine, University of Cantabria, Santander 39011 Cantabria, Spain. 3Centro
de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de
Salud Carlos III, Madrid 28029, Spain. 4Instituto de Neurociencias, UMH-CSIC,
Alicante 3550, Spain. 5Instituto de Biomedicina y Biotecnología de Cantabria,
IBBTEC (Universidad de Cantabria, CSIC, SODERCAN), 39011 Santander,
Cantabria, Spain. 6Department of Physiology and Pharmacology, School of
Medicine, University of Cantabria, Santander 39011 Cantabria, Spain. 7Infection,
Immunity and Digestive Pathology Group, University Hospital Marqués de
Valdecilla-IDIVAL, Santander 39011 Cantabria, Spain. 8Department of Psychiatry,
Sierrallana Hospital, Torrelavega 39300 Cantabria, Spain. 9Institute of
Parasitology and Biomedicine “López-Neyra” (IPBLN-CSIC), Armilla 18016
Granada, Spain. 10Department of Molecular Biology, Centro de Biología
Molecular “Severo Ochoa” (UAM-CSIC), Universidad Autónoma de Madrid,
Madrid 28049, Spain. 11Centro de Investigación Biomédica en Red de
Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid
28029, Spain. 12Department of Pharmacology, University of the Basque
Country UPV/EHU, Leioa 48940 Bizkaia, Spain. 13Department of Physiology and
Biophysics, Virginia Commonwealth University School of Medicine, P.
O. Box 980551Molecular Medicine Research Building 5-038, Richmond 23298
Virginia, USA. 14Department of Psychiatry, School of Medicine, University
Hospital Virgen del Rocio-IBiS, Sevilla 41013, Spain
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Supplementary Information accompanies this paper at (https://doi.org/
10.1038/s41398-019-0647-7).
Received: 8 May 2019 Revised: 8 October 2019 Accepted: 20 October 2019
References
1. Chouinard, G. et al. Antipsychotic-induced dopamine supersensitivity psy-
chosis: pharmacology, criteria, and therapy. Psychother. Psychosom. 86,
189–219 (2017).
2. Seeman, P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin.
Ther. Targets 10, 515–531 (2006).
3. Rampino, A. et al. Antipsychotic drug responsiveness and dopamine receptor
signaling; old players and new prospects. Front. Psychiatry 9, 702 (2018).
4. Aringhieri, S. et al. Molecular targets of atypical antipsychotics: from
mechanism of action to clinical differences. Pharm. Ther. 192, 20–41 (2018).
5. Fusar-Poli, P. et al. Treatments of negative symptoms in schizophrenia: meta-
analysis of 168 randomized placebo-controlled trials. Schizophr. Bull. 41,
892–899 (2015).
6. Meltzer, H. Y. Treatment-resistant schizophrenia–the role of clozapine. Curr.
Med. Res. Opin. 14, 1–20 (1997).
7. Elkis, H. Treatment-resistant schizophrenia. Psychiatr. Clin. North Am. 30,
511–533 (2007).
8. Gillespie, A. L., Samanaite, R., Mill, J., Egerton, A. & MacCabe, J. H. Is treatment-
resistant schizophrenia categorically distinct from treatment-responsive schi-
zophrenia? a systematic review. BMC Psychiatry 17, 12 (2017).
9. Stone, J. M. Glutamatergic antipsychotic drugs: a new dawn in the treatment
of schizophrenia? Ther. Adv. Psychopharmacol. 1, 5–18 (2011).
10. Nordstrom, A. L. et al. D1, D2, and 5-HT2 receptor occupancy in relation to
clozapine serum concentration: a PET study of schizophrenic patients. Am. J.
Psychiatry 152, 1444–1449 (1995).
11. Miller, R. Mechanisms of action of antipsychotic drugs of different classes,
refractoriness to therapeutic effects of classical neuroleptics, and individual
variation in sensitivity to their actions: Part I. Curr. Neuropharmacol. 7, 302–314
(2009).
12. Wisler, J. W., Xiao, K., Thomsen, A. R. & Lefkowitz, R. J. Recent developments in
biased agonism. Curr. Opin. Cell Biol. 27, 18–24 (2014).
13. Wang, H., Farhan, M., Xu, J., Lazarovici, P. & Zheng, W. The involvement of
DARPP-32 in the pathophysiology of schizophrenia. Oncotarget 8,
53791–53803 (2017).
14. Nishi, A. et al. Glutamate counteracts dopamine/PKA signaling via depho-
sphorylation of DARPP-32 Ser-97 and alteration of its cytonuclear distribution.
J. Biol. Chem. 292, 1462–1476 (2017).
15. Nicoletti, F., Bruno, V., Ngomba, R. T., Gradini, R. & Battaglia, G. Metabotropic
glutamate receptors as drug targets: what’s new? Curr. Opin. Pharm. 20, 89–94
(2015).
16. Sainz, J. et al. Inflammatory and immune response genes have sig-
nificantly altered expression in schizophrenia. Mol. Psychiatry 18,
1056–1057 (2013).
17. Crespo-Facorro B., Prieto C., Sainz J. Schizophrenia gene expression profile
reverted to normal levels by antipsychotics. Int. J. Neuropsychopharmacol. 18,
pii: pyu066 (2014).
18. Pelayo-Teran, J. M. et al. Epidemiological factors associated with treated inci-
dence of first-episode non-affective psychosis in Cantabria: insights from the
Clinical Programme on Early Phases of Psychosis. Early Inter. Psychiatry 2,
178–187 (2008).
19. Llerena, S. et al. Applied diagnostics in liver cancer. Efficient combinations of
sorafenib with targeted inhibitors blocking AKT/mTOR. Oncotarget 9,
30869–30882 (2018).
20. Zhang H., Nielsen A. L., Stromgaard K. Recent achievements in developing
selective Gq inhibitors. Med. Res. Rev. 1–23 (2019).
21. Phillipson, O. T. Afferent projections to the ventral tegmental area of Tsai and
interfascicular nucleus: a horseradish peroxidase study in the rat. J. Comp.
Neurol. 187, 117–143 (1979).
22. Khlghatyan J., Quintana C., Parent M., Beaulieu J. M. High sensitivity mapping
of cortical dopamine D2 receptor expressing neurons. Cereb. Cortex 29,
3813–3827 (2018).
23. Lopez-Gimenez, J. F. et al. Validation of schizophrenia gene expression profile
in a preclinical model of maternal infection during pregnancy. Schizophr. Res.
189, 217–218 (2017).
24. Khokhar, J. Y., Henricks, A. M., Sullivan, E. D. K. & Green, A. I. Unique effects of
clozapine: a pharmacological perspective. Adv. Pharm. 82, 137–162 (2018).
25. Rice, M. W., Roberts, R. C., Melendez-Ferro, M. & Perez-Costas, E. Mapping
dopaminergic deficiencies in the substantia nigra/ventral tegmental area in
schizophrenia. Brain Struct. Funct. 221, 185–201 (2016).
26. Howes, O. D. & Kapur, S. The dopamine hypothesis of schizophrenia: version
III–the final common pathway. Schizophr. Bull. 35, 549–562 (2009).
27. Kapur, S., Zipursky, R., Jones, C., Remington, G. & Houle, S. Relationship
between dopamine D(2) occupancy, clinical response, and side effects: a
double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 157,
514–520 (2000).
28. Mead, T. J. & Apte, S. S. ADAMTS proteins in human disorders. Matrix Biol. 71-
72, 225–239 (2018).
29. Kelwick, R., Desanlis, I., Wheeler, G. N. & Edwards, D. R. The ADAMTS (a dis-
integrin and metalloproteinase with thrombospondin motifs) family. Genome
Biol. 16, 113 (2015).
30. Colige, A. et al. Domains and maturation processes that regulate the activity of
ADAMTS-2, a metalloproteinase cleaving the aminopropeptide of fibrillar
procollagens types I-III and V. J. Biol. Chem. 280, 34397–34408 (2005).
31. Bekhouche, M. et al. Determination of the substrate repertoire of ADAMTS2, 3,
and 14 significantly broadens their functions and identifies extracellular matrix
organization and TGF-beta signaling as primary targets. FASEB J. 30,
1741–1756 (2016).
32. Berretta, S. Extracellular matrix abnormalities in schizophrenia. Neuropharma-
cology 62, 1584–1597 (2012).
33. Benes, F. M. et al. Regulation of the GABA cell phenotype in hippocampus of
schizophrenics and bipolars. Proc. Natl Acad. Sci. USA 104, 10164–10169 (2007).
34. Hoseth, E. Z. et al. Exploring the Wnt signaling pathway in schizophrenia and
bipolar disorder. Transl. Psychiatry 8, 55 (2018).
35. Pietersen, C. Y. et al. Molecular profiles of parvalbumin-immunoreactive neu-
rons in the superior temporal cortex in schizophrenia. J. Neurogenet. 28, 70–85
(2014).
Ruso-Julve et al. Translational Psychiatry           (2019) 9:306 Page 11 of 12
36. Pietersen, C. Y. et al. Molecular profiles of pyramidal neurons in the superior
temporal cortex in schizophrenia. J. Neurogenet. 28, 53–69 (2014).
37. Miller, R. Mechanisms of action of antipsychotic drugs of different classes,
refractoriness to therapeutic effects of classical neuroleptics, and individual
variation in sensitivity to their actions: Part II. Curr. Neuropharmacol. 7, 315–330
(2009).
38. Paul, M. L., Graybiel, A. M., David, J. C. & Robertson, H. A. D1-like and D2-like
dopamine receptors synergistically activate rotation and c-fos expression in
the dopamine-depleted striatum in a rat model of Parkinson’s disease. J.
Neurosci. 12, 3729–3742 (1992).
39. Belgacem, Y. H. & Borodinsky, L. N. CREB at the crossroads of activity-
dependent regulation of nervous system development and function. Adv. Exp.
Med. Biol. 1015, 19–39 (2017).
40. Carlezon, W. A. Jr., Duman, R. S. & Nestler, E. J. The many faces of CREB. Trends
Neurosci. 28, 436–445 (2005).
41. Lonze, B. E. & Ginty, D. D. Function and regulation of CREB family transcription
factors in the nervous system. Neuron 35, 605–623 (2002).
42. Aringhieri, S. et al. Clozapine as the most efficacious antipsychotic for acti-
vating ERK 1/2 kinases: role of 5-HT2A receptor agonism. Eur. Neuropsycho-
pharmacol. 27, 383–398 (2017).
43. Schmid, C. L., Streicher, J. M., Meltzer, H. Y. & Bohn, L. M. Clozapine acts as an
agonist at serotonin 2A receptors to counter MK-801-induced behaviors
through a betaarrestin2-independent activation of Akt. Neuropsychopharma-
cology 39, 1902–1913 (2014).
44. Lukasiewicz, S., Faron-Gorecka, A., Kedracka-Krok, S. & Dziedzicka-Wasylewska,
M. Effect of clozapine on the dimerization of serotonin 5-HT(2A) receptor and
its genetic variant 5-HT(2A)H425Y with dopamine D(2) receptor. Eur. J. Pharm.
659, 114–123 (2011).
45. Wang, H., Xu, J., Lazarovici, P., Quirion, R. & Zheng, W. cAMP response
element-binding protein (CREB): a possible signaling molecule link in
the pathophysiology of schizophrenia. Front. Mol. Neurosci. 11, 255
(2018).
46. Seamon, K. B., Padgett, W. & Daly, J. W. Forskolin: unique diterpene activator of
adenylate cyclase in membranes and in intact cells. Proc. Natl Acad. Sci. USA
78, 3363–3367 (1981).
47. Zhang, G., Liu, Y., Ruoho, A. E. & Hurley, J. H. Structure of the adenylyl cyclase
catalytic core. Nature 386, 247–253 (1997).
48. Del’guidice, T., Lemasson, M. & Beaulieu, J. M. Role of beta-arrestin 2 down-
stream of dopamine receptors in the basal ganglia. Front. Neuroanat. 5, 58
(2011).
Ruso-Julve et al. Translational Psychiatry           (2019) 9:306 Page 12 of 12
